HER3 (ERBB3) amplification in liposarcoma - a putative new therapeutic target?

Area of Science:

• Oncology
• Molecular Pathology
• Genetics

Background:

• Liposarcomas are common mesenchymal tumors with limited therapeutic options.
• Current treatments and immunotherapies show limited efficacy in liposarcoma.
• Accurate classification is challenging due to morphological diversity and non-specific markers, necessitating molecular diagnostics.

Purpose of the Study:

• To investigate the potential of HER3 (ERBB3) as a therapeutic target in liposarcoma.
• To explore the co-amplification of HER3 with MDM2 gene amplifications in liposarcoma.

Main Methods:

• Fluorescence in situ hybridization (FISH) analysis was performed on 56 archived liposarcoma cases.
• Genes analyzed included MDM2, DDIT3, and HER3.
• Cases were reclassified based on molecular pathology findings.

Main Results:

• 16 out of 56 cases required reclassification.
• HER3 co-amplification with MDM2 amplification was detected in 20 out of 54 cases.
• Profuse HER3 cluster-amplification was observed in 57.1% of cases, indicating a potential therapeutic target.

Conclusions:

• Liposarcomas exhibit distinct molecular characteristics that aid in reclassification.
• HER3 gene amplification presents a putative therapeutic target for targeted therapy in liposarcoma.
• Further investigation into HER3 as a therapeutic target in liposarcoma is warranted.